• In April 2026, Becton, Dickinson and Company voluntarily initiated worldwide Class II recalls of several Swan-Ganz and Swan-Ganz Jr catheter models after US regulators reported that manufacturing and material changes could cause leaks or breaks at the proximal injectate lumen hub, risking infection, medication loss, or blood loss for patients.
• With more than half a million devices affected across hospitals in the US and dozens of other countries, the episode highlights how quality control issues in a specialized but globally distributed product line can create meaningful operational, legal, and reputational questions for a major medical device maker.
• Against this backdrop, we’ll examine how the worldwide Swan-Ganz catheter recalls reshape Becton Dickinson’s investment narrative around product safety and execution.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 27 companies in the world exploring or producing it. Find the list for free.

What Is Becton Dickinson's Investment Narrative?

To own BD today, you need to believe in a diversified, global medical technology franchise that can convert steady but unspectacular revenue growth, a long dividend track record and a deep product pipeline into durable cash flows, despite high debt and a recent one off loss that distorted GAAP earnings. The key near term catalysts still sit in execution: rolling out new platforms like Pyxis Pro, Alaris upgrades and interventional launches, and proving that the refreshed leadership team can keep margins and cash generation on track. The nationwide and worldwide Swan Ganz Class II recalls add a fresh layer of product quality and legal risk, but based on the stock’s prior underperformance and the size of BD’s portfolio, the financial hit may be more about elevated scrutiny and potential litigation than a clear change to the core investment case.

However, the Swan Ganz recalls introduce an execution risk that investors should not ignore. Becton Dickinson's shares have been on the rise but are still potentially undervalued by 22%. Find out what it's worth.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span US$181 to around US$253, reflecting very different expectations. Set those against BD’s recent recall driven quality concerns and you can see why many readers will want to review how product risk might influence their own view on the company’s long term performance.

Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth just $181.23!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Becton Dickinson research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.